BioMedNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference

NanoViricides (NYSE American: NNVC), a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–11, 2023, in New York City. Company president Anil R. Diwan, PhD, will be presenting at the gathering; his presentation is scheduled May 10. The global conference is an elite, invitation-only event featuring key executives from some 150 public and private companies; company executives are invited to present the unique stories of their companies to institutional investors, high-net worth individuals, corporate clients and members of the press; one-on-one meetings are also available during the conference. According to the announcement, companies from an array of industries will be presenting; sectors represented include consumer and retail, energy and infrastructure, financial services, healthcare and life sciences, industrials, real estate, gaming, lodging, sustainability, technology, media and telecommunications.

To view the full press release, visit https://ibn.fm/vzvts

About NanoViricides Inc.

NanoViricides is a clinical-stage company that is creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Each nanoviricide drug is designed so that virus variants would be highly unlikely to escape the drug, solving a critical issue in antiviral drug development. The company’s lead drug candidate for the treatment of COVID and long COVID caused by SARS-CoV-2 coronavirus is approved to enter human clinical trials that are expected very soon. The company’s other advanced candidate is NV-HHV-1 for the treatment of shingles, which has completed IND-enabling safety/pharmacology studies. NV-CoV-2 is the company’s nanoviricide drug candidate for COVID. NV-CoV-2-R is another drug candidate for COVID that is made up of NV-CoV-2 with Remdesivir, an already approved drug, encapsulated within its polymeric micelles. Remdesivir is developed by Gilead. The company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently. The company is also developing a broad pipeline of drugs against a number of viruses, with preclinical safety and effectiveness successes achieved already in many cases. For more information about the company, please visit www.NanoViricides.com

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork